Clinical infection control in gene therapy: a multidisciplinary conference.
Gene therapy is being studied for the treatment of a variety of acquired and inherited disorders. Retroviruses, adenoviruses, poxviruses, adeno-associated viruses, herpesviruses, and others are being engineered to transfer genes into humans. Treatment protocols using recombinant viruses are being introduced into clinical settings. Infection control professionals will be involved in reviewing the safety of these agents in their clinics and hospitals. To date, only a limited number of articles have been written on infection control in gene therapy, and no widely available recommendations exist from federal or private organizations to guide infection control professionals. The goals of the conference were to provide a forum where gene therapy experts could share their perspectives and experience with infection control in gene therapy and to provide an opportunity for newcomers to the field to learn about issues specific to infection control in gene therapy. Recommendations for infection control in gene therapy were proposed.
Evans
M E
ME
Division of Infectious Diseases, University of Kentucky College of Medicine, Chandler Medical Center, Lexington, USA.
Jordan
C T
CT
Chang
S M
SM
Conrad
C
C
Gerberding
J L
JL
Kaufman
H L
HL
Mayhall
C G
CG
Nolta
J A
JA
Pilaro
A M
AM
Sullivan
S
S
Weber
D J
DJ
Wivel
N A
NA
D003226:Congresses as Topic; D005260:Female; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods / Q000639:trends; D017408:Guidelines as Topic; D006801:Humans; D017053:Infection Control / Q000379:methods / Q000592:standards; D014481:United States; D014486:United States Food and Drug Administration; D014777:Virus Diseases / Q000628:therapy*